Applying the proposed method to the MEGA study data , several prognostic factors are associated with the censoring processes , and after adjusting for these dependent censorings , slightly larger treatment effects for pravastatin are observed for both CHD ( primary endpoint ) and stroke ( secondary endpoint ) events .
